Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good day and welcome to the Devyser Q1 2025 Earnings Call. I'm Fredrik Dahl, the acting CEO of Devyser, and I would like to thank everyone for joining our call today. On the call today, we have, in addition to myself, our CFO, Sabina Berlin, and our Chief Commercial Officer, Theis Kipling. I will start with a short summary of our quarterly results, then recap our updated strategy and present some highlights from the team before handing over to Sabina for a more detailed review of our financial results in Q1 2025, and then to Theis for an update on our commercial activities. We had another solid quarter based on revenue, marking the second strongest quarter in the company's history. The revenue was 55 million SEK, representing a growth of 8% compared to Q1 last year. Gross margins were 83% and EBIT stood at -21 million SEK, including 8 million SEK in one-offs related to reorganization and another 6 million SEK in F/X headwinds. Our cash position was 114 million SEK. Um, as mentioned on the previous call, we have made some updates to our strategy that we have now started to execute. The overall goal for us in the company in the coming year is to make Devyser a more efficient organization. And that goal starts with a clearer and more focused strategy. As mentioned, we propose focusing on two customer segments: the Clinical Genetic Labs and Transplantation Laboratories. We strongly believe there are significantly more unmet diagnostic needs that we can address here, together with our customers and scientific collaborators. We are now in the process of updating our product roadmap by reaching out to our top customers and asking them what they need help with. This voice of customer exercise will guide us to better prioritize which products we should develop in the coming years. Transplantation diagnostics has undergone a paradigm shift with the introduction of cell-free DNA as a sensitive diagnostic marker to measure transplant rejection. We're trying to transform how this diagnostic is carried out by bringing the test closer to the patient, instead of shipping samples out to service labs with long turnaround times and high costs. We propose to provide products directly to the transplantation labs, where patients meet the medical and scientific expertise. This results in decreased turnaround time, better accessibility for patients, lower prices, and without compromising on performance. During the quarter, we have identified a number of customers in the US that are ready to adopt our cfDNA product today through self-validation, even before an FDA approval is in place. In addition to a good business opportunity, it confirms our strategy on decentralizing the test, and dialogue with key stakeholders is ongoing. With many of these large transplantation labs, the overall opportunity for Devyser remains very promising. As part of the transplantation strategy, we have initiated an FDA project, as previously communicated, to provide more clarity into the process. We have now started to collect samples and qualified partnering transplant centers. The project scope is quite straightforward, including just a handful of centers with a few hundred samples needed to carry out the required reproducibility and accuracy studies. This timeline will be communicated later this year. Um, so if you highlight. So I would like to highlight a few activities from the quarter, starting with R&D and product updates. One of the most exciting meetings we had this past quarter was with a collaborator in Texas that carries out about 1,500 transplantations per year. Uh, they are reluctant to send out samples to service labs and have now started to work on evaluating our technology in-house for self-certification. This is not only a great commercial opportunity, but more importantly, it confirms our strategy regarding the decentralization of transplantation diagnostics. We're now in the process of initiating more of these labs in the US. Continue with transplantation. We have developed a product to address an unmet and very important clinical need in patients with malignant disease after stem cell transplantation. The product is called HLA Loss and will be launched before summer, representing a unique and premium product in the segment. This is something we are very excited about. Another upcoming launch is our Genomic Blood Group Typing, which represents a tool for typing blood donors and has the potential to transform the field of transfusion medicine. We expect to launch this product during the summer and release more information on that. Finally, we're just weeks away from submitting our reimbursement application to MolDx for our post-transplantation test as a service called Transplant Trace. cfDNA product. We expect confirmation after the summer and are, in parallel, building up our commercial channel with some of the largest transplantation institutions and companies. Um, I would like to add a few more highlights from the team that deserve mentioning. Um, as previously announced, in late 2024, we achieved IVDR Class D approval from our external regulatory assessment on our Devyser RHD product. We have now finalized our internal quality process that enables us to start shipping the product. Um, and this is the highest risk classification under EU regulation. And get it over the line, so to speak. Speaks to the strength of both our technical and regulatory teams. We have now demonstrated that we can deliver class D products end-to-end, from development to batch release and shipping directly to customers. And because we built a scalable regulatory and quality framework, we are well positioned to support the development of any IVD product, regardless of risk class. As we continue to grow our company and portfolio forward, moving on to production, there are still many low-hanging fruits to get our manufacturing more streamlined and efficient. We have initiated a number of value-generating projects, such as the introduction of additional liquid handling automation and projects to extend the shelf life of our products. Therefore, we are confident that there are still plenty of opportunities to increase gross margins even further from where we are today. Finally, we have been able to execute the majority of initiated organizational changes in Q1 by increasing focus and efficiency. These changes have been executed without compromising top-line growth nor delaying any development projects. This initiative is key for the company to reach our financial targets of 20% EBIT by 2026. And with that, I would like to hand over to Sabina to share more details on our financial results for Q1 2025.
Thank you, Fredrik. So let's give you a summary of the financials for the quarter. Revenue for the period January to March came in at 54.8 million SEK, compared to 50.7 million SEK in the same quarter last year and 64.2 million SEK in Q4 of last year. Growth of 7.9% in the quarter is lower than what we saw in Q4. But as stated many times, there will always be fluctuations in individual quarters. We continue to see the same strong trajectory as we have in historical years. This will soon provide some additional information about the performance of our different markets during the past few months. Despite the lower than average growth between two quarters, this was still the second largest quarter revenue-wise in the company's history. Company history. As Fredrik stated early on in the call. Our EMEA region remains our biggest market, but it grew less than usual this quarter, although with a strong underlying growth trend. USA has taken some market share and Asia-Pacific continues to show strong growth, although still from small numbers. It should be noted in this table that Thermo Fisher sales are split between EMEA and the US as we ship to both US and European Thermo warehouses. Distributor sales this quarter consist of a mix of a few smaller Thermo Fisher orders and a healthy sales funnel from our smaller distributors globally. Our distributor sales business is well-managed and steadily growing. Our direct markets, as previously mentioned, showed a softer quarter overall, with some markets performing very well and some slightly below average, mainly due to overlapping quarters, which Theis will also cover shortly. Gross margin, it came in at 83.4% during the quarter after a softer 2024, and shows that we are back on track and have started gaining momentum from the expanded office facility with a new manufacturing section, a momentum that we expect to continue. EBIT during the quarter was -21 MSEK during the period of January to March. Several additional savings initiatives were initiated to right-size. The cost base and the personnel include about 8 million SEK in one-off items from those initiatives. Some of these initiatives carry over into the beginning of Q2 before we see the updated run rate going forward. The quarter was also heavily impacted by an unusually strong Swedish krona, and EBIT carries about 6 million SEK in negative FX impact from the balance sheet alone. Comparing EBIT with that of Q1 last year, adjusted for the impact from one-offs and FX, the main operations of the company show an improvement over last year. We closed the quarter with 114 million SEK in cash, and I feel comfortable that our cash flow will improve over the foreseeable period as our focus on profitability continues. And with that, I hand over to Tyson.
Thank you, Sabina, and good morning from Boston here in the US, where I'm attending the annual conference for solid organs focusing on heart and lung. Together with Thermo Fisher. And what a great week in Boston. This already is. I can tell you Q1 of 2025 was, as mentioned. Our second-best revenue quarter in the history of the company. Despite the expected softness in revenues from Thermo Fisher, we advanced our business on many fronts, launched our new strategy, optimized our cost structure, and most importantly, we continued to onboard more new customers, which I will update you on here in the coming slides. Moving up and updating you on Thermo Fisher. Q1 was decent even despite the very strong Q4 of last year, including the stock-up effects mentioned for Thermo Fisher on their side. We continue to win over large new accounts, as Fredrik also mentioned in his slides earlier. And generally, we see Thermo Fisher drive the market expansion in a very strong manner across both Europe and North America, while gradually establishing the business outside these territories. And I've had many potential customers here at this conference outside Europe and North America coming to us and asking how they can get started with testing cfDNA. So it's a very promising outlook. The FDA program continues to follow the plan, and we are engaging with several clinical sites within the US to assist us, along with the studies needed for the FDA application as communicated. This is basically only about replicating data that we have from Europe already. We know that the product works well, and hence this is not a question of if, but it's only a matter of when the FDA approval will come. A general update on North America. As Fredrik mentioned, within our lab, we are soon planning on submitting our reimbursement application to MolDx related to our transplant. Transplant Trace cfDNA test for solid organs. Reimbursement is expected during the second half of 2025 and is an important milestone that will be instrumental in the current conversations we are having with potential partners within the US about commercializing the services for solid organs. We have also already submitted for reimbursement for our HD service in our Atlanta based Clear Lab, and await confirmation during Q3. The new Cyted contracts are being delivered on, and there is a lot of activity every week, which we anticipate will only ramp up continuously during the months ahead of us. Art, Dean Canada is starting to generate revenues with Canadian Blood Services, especially as they start testing in larger volumes, while Héma-Québec is expected to reach this a little later on within the US. We continue our work with RDI across different channels, and I remain confident that we're still only at the very onset of our RDI success story here in the States. During Q1, we hosted a US-focused webinar on RDI together with the prestigious CAP Today, featuring two talks from Canadian Blood Services and Héma-Québec in Canada, which generated a lot of interest. And during this year, we will announce more about whom we will be partnering with to conduct RDI testing in the US prior to the prophylactic treatment, as is the current standard. Lastly, we're now starting to see our first customers using our test for cystic fibrosis in clinical routine testing, which is also very promising. Generally, our growth in the US will come from across our product technology areas. Both PCR, next-generation sequencing, and fragment analysis will be accelerated by our clear lab. Moving on to Europe, I'm pleased to see that across our markets in Spain, France, and the UK, we actually had growth of around 50% versus Q1 of 2020. We were impacted by some large customers placing their orders in late Q4 of last year, which affected and softened Q1 of this year. As Sabina has mentioned, the underlying growth and the outlook, however, look strong. Also in these markets, and as you may have seen, we announced another very strong tender win in Italy just last week with an incremental growth of 10% over the previous tender. Generally, across Europe in Q1, we had 10% more buying customers than the same period last year, and the average selling prices, excluding transplantation, were 13% above last year as well. Devyser is leading across Europe when it comes to IVD certified products, which is a quality reassurance to our customers that we are the safe choice when considering new products for their labs. The new IVDR regulation comes into full effect in just a couple of years now, and hence Devyser is in a very strong position to leverage the regulatory leadership that we already have. Q1 was indeed a busy quarter where we especially focused on the launch of the new strategy. That was a key milestone. We are already, for many labs, a preferred one-stop shop, and I'm confident that this is a position we can claim across all our direct markets over time. We're now gearing up to launch several new products and software solutions alongside our collaborations during the remainder of the year, which will further support our growth. As an example, when looking at our four most recent product launches, they accounted for approximately 18% of total revenues in the past year. And with that, I pass the word back to you, Fredrik.
Thank you. Tyson. Sabina. The theme for 2025 is to leverage our recent investments, focus the organization, and turn the company around to profitability towards our financial targets. With all the exciting product launches, internal activities, and commercial focus, I'm confident we will turn the company around and achieve these goals. With that, I would like to open up for questions.
To ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key on your telephone keypad. The next question comes from Philip Wiberg from Pareto Securities. Please go ahead.
Hi. Um, so I've got a couple of questions here. Um, perhaps I'll start with just a question about the distributor sales here. Um, so Thermo Fisher orders have been in focus now for the past quarters. And you know, it's almost half now since Q4. And that's not entirely unexpected, but I was just wondering if you could say anything more about what you're expecting moving forward. As you said, there were some small orders in this quarter, but are you expecting any big ones going forward like we saw in Q4, for instance?
Um, yeah. Hi, Philipp. So no, as we usually answer, we don't guide on any specific customers. Um, and that's true for Thermo as well. So there are orders coming in, as mentioned both in Q1, and it continues in Q2. But, uh, no, no further guidance.
We're now gearing up to launch several new products and software solutions alongside our collaborations during the remainder of the year, which will further support our growth. All right. Um, and then perhaps on the growth rate here now for this year, you started a bit slow and also a bit as expected, but you also have a financial target to reach 30% organic growth per year. So how confident would you say that you will reach that during 2025?
Well, we're very confident that we're going to meet all the goals and milestones that we have set out. Goals and milestones that we have set out. Um, as Sabina mentioned, there are fluctuations from quarter to quarter. But for the full year, there is no reason for us to change any guidance. Um.
Okay. Now, I think they also talked a bit about launching new tests and additional customers coming up. You have reimbursement. So it sounds like it's going to be pretty heavily tilted towards the second half. Is that a correct assumption then?
Uh, I think that's fair to say. I mean, but there's definitely still activities we're seeing, as Theis mentioned also, that we definitely see more activity with Thermo Fisher. Um, and uh, I think, uh, in a in a very good way. So, um, it's true. It's a, it's a fair assumption.
Okay. Well, we're very confident that we're going to meet all the. Um, and perhaps just the last one for me then. Well, we're very confident that we're going to meet all the. So, all of these restructuring costs, these one-off effects, you mentioned there are some that will now extend into Q2 as well, but is it possible to provide any sort of quantification regarding how much that is in relation to what we observed in Q1?
Um, Sabina, maybe you want to take that one.
Uh, we will not delve into the details, but I can say that it's only the tail end of the restructuring that will impact Q2. And the main changes were carried out in Q1.
All right. Well, we're very confident that we're going to meet all the goals and milestones that we have set out. Yeah. Thanks for that. That's all from me.
Question comes from Ulrich Trattner from Carnegie. Please go ahead.
Hi, it's Clara from Carnegie. I'm here on behalf of Ulrich. And so, you're mentioning your restructuring. Can you clarify a bit more about what this entails?
Um, without going into any specifics. So, as communicated on the last earnings call and the recap today, we have updated the strategy to focus on these two customer segments: the clinical genetics labs and transplantation. And what we have done is to just make a few adjustments to the organization that better reflect this updated strategy.
Hi, it's Clara from Carnegie. Hi, it's Clara from Carnegie. So I have one more question. You mentioned that Europe is going quite well. If I understood it right, is there a trend shift that we see in the direct sales in Europe?
Um, maybe you want to take that one.
Uh, yes, I can do that. No, no, I mean there's no trend shift in any way. I mean, the underlying demand is solid, right? So we just saw a little bit of phasing here, with Italy especially being slower in Q1. Um, and other markets were really delivering and over-delivering, honestly. So, um, no, no trend. Everything is moving, and as I said, we are increasing the number of buying customers. We're increasing the prices not only for Europe but across the board. So it's a very healthy state.
I could say that we're particularly pleased with our performance in some regions.
Perfect.
That we're, you know, particularly happy with the fact that some of the regions outside Italy and Europe are picking up pace. Um, and as you know, uh, everyone who's working with diagnostics, you know, it takes time. Uh, but when you have traction in diagnostics, it tends to be a very sticky business. And I think that's what we're capitalizing on right now in regions outside Italy. And it's very, very exciting actually.
Thank you very much for those answers. If it's okay, I have one last question. Um, so what do you think is expected in terms of Thermo Fisher's destocking effects in the second quarter?
Um, no, I think I will refer to the same answer as I did previously, that we're not providing any specifics about the Thermo Fisher orders. The orders are coming in both here in Q1 and Q2, but no further guidance.
Okay. Thank you very much.
The next question comes from Oskar Bergman from Redeye. Please go ahead.
Hello, everyone. Um, I got a few questions. Uh, the first one is, if you can elaborate on the sales development and its, uh, its drivers in Italy specifically, and just some comments on how much more you can actually get out of this market.
Do you want to take that one?
Yeah. I mean, that's a good question, Oskar. I think, uh, take the most recent tender as a good example. Um, there, we're seeing at least a 10% incremental growth on that tender. Italy, in historic terms, has been growing at a modest double-digit or high single-digit rate. Uh, I don't see anything that will change that in any way. So it's a very robust business. We are clearly the market leader in many areas, and we are certainly the one-stop shop. This is the market where we have the most traction with this strategy of becoming a one-stop shop. And that will accumulate. So Italy will continue.
Okay. All right. So I guess, sort of a follow-up question on that because, as you said, we see tenders have increased from previous agreements. And I was wondering if you can explain what drives these increases. Is it mainly pricing? Is it new tests or more of the same tests? I mean, is it driven by cross-selling and upselling, or is it just more of the same?
Yeah. You can.
Yeah, it's a combination. So, um, whenever there's a, you know, a reopening of a new tender, that's our opportunity to also impose, uh, more of the increased, uh, prices beyond what has been otherwise stated in the contract of the tender, uh, so that there's a value increase in terms of how we manage, uh, and work with pricing. But beyond that, we're successfully adding more and more products into the same tenders. Right. So doing demos, presenting new opportunities. And by that, we're enlarging the tender scope to include more Devyser products.
Maybe just a short comment on pricing. So sorry, Oscar. So maybe as a short follow-up on pricing, what we have noticed is that we're not losing any customers, very, very rarely. Um, and I would say it's fair to say that there is room for looking at the prices on our products to see what we can do there. Um, but clearly we're not, we're not, um, at the point where the customer feels that they, they, uh, need to look at alternatives.
Mm. Okay. And I suspect you can implement the price increases once you receive new tenders. Or can you go and sort of make changes in existing tenders for price increases?
Right. Yes.
Yeah. So, uh, no, usually tenders and any contract are, uh, restricted or gated. So there's only a certain increase that you're allowed. Right. So if you really want to have, uh, bigger changes, it has to be when you roll that tender over to a new tender. So that's the usual pattern.
All right. And I think, um, I don't know when you said this, I think maybe it was, um, in November sometime, but there was a presentation where you mentioned that, um, you have high expectations for the US market. But what's interesting when you make that sort of statement is a sort of timeline for it. So I was just wondering if you can give some sort of timeline of when the US could actually be a bigger market than Italy.
You know, I think it's a question for you.
Yeah. I think I'll stay with Fredrik's comments from before. Right. We, uh, don't provide this type of guidance, but it's on a good track. I can tell you.
Okay. I can always try to get some sort of answer. You just have a few more questions before I head back into the queue. Um, it's very interesting to see the geographical sales development. Uh, unfortunately, we sort of have to wait for the annual reports to see this in any detail. Um, is this something that you are looking into providing on a quarterly basis as well?
Sabina.
Um, well, their annual report tends to, uh, provide more details in general. And so far, we've been focusing on our biggest regions in the quarterly reports. But we'll take your feedback with us and, uh, we'll see when we can provide more details on a quarterly basis.
Yeah. And we know that in Q4. There was also some shifts with some customers who were transitioned. I guess you can say to Thermo Fisher Scientific. Was this also the case in Q1, or was all of that transition finalized in Q4?
Yeah. Sabina Berlin ties.
Yeah, I can, I can start. It was transitioned during last year. So that's to be considered also in the comparison to last year. So some of it has now shifted to distributor sales in our Q1 report.
Yeah. All right. And then the conversion of the distributor market to direct markets. Can you elaborate on this progress in Q1 and how you expect this to develop for the rest of 2025?
Uh, Theis Kipling? You can take that one.
Yeah. I mean, we have markets in scope that could be converted, but right now, we're not making any active changes. We're doubling down on the markets. We have already made that conversion into direct and have put our own team on the ground. We want to ensure that we apply the necessary focus to truly deliver and double down before we add more markets. But there is a nice tail of additional markets where we certainly could and will convert in time, but not in the near future in any way.
You can take that one. And would you say, you know, with the, uh, transplantation tests and an increasing focus on that part of your business, that the conversion of distributor markets to direct markets in Europe is something that would be less prioritized going forward.
Please continue.
Uh, no, I would answer no. No, I mean, we focus on all the strategic imperatives that we have, and converting markets directly is also a significant growth enabler for us. Right. But we want to make sure that we have the right approach for doing it. And we have just implemented some right-sizing in the organization. We're really focusing on doubling down on growth. Um, and that's the focus before we start expanding further.
You can take that one. All right. And I promise, this is my last question. Um, is there any reason to sort of be prepared for any risk of a negative impact on sales, uh, and increasing costs in the short term due to this updated strategy? Anything that can halt selling activities and marketing activities and so on.
Um. I'm not sure I'm answering the question, but we are looking at our business today with the adjustments we have made. We feel we're building a very solid foundation for further growth. Um, I think we have, uh, done the great majority of the changes that we have planned when we started this year. Um, and we have started to execute as a company much more efficiently. And I'm very confident that this trend will become even stronger going forward. Um, so, um, I'm not sure I answered the question correctly, but.
I think you did, uh, use to, uh, to be sure, um, I think Philip asked previously in this call about your expectations of, uh, of your sales target. And it seems like you're very confident that you will be able to deliver on the 30% organic growth target for 2025. Also.
Yeah, I mean, if you look at the history of the company, you have seen fluctuations, uh, during the year, right. And, uh, we are seeing a good, solid funnel going forward. We have very exciting new releases of products coming up. Um, we have, uh, the MolDx application that's going to be submitted within weeks, which we expect to go live after the summer. So, uh, we have, uh, so many exciting opportunities here, uh, in addition to Thermo picking up speed, uh, that, uh, we're, uh, we think we're in very good shape.
And it seems like you're very confident that you will be able to deliver on the 30% organic growth target for 2025. And I know that this target was set before the Thermo Fisher deal. So, um, if the Thermo Fisher deal were not in place, would you still be as confident in this sales target as you seem to be today?
So if the Thermo Fisher deal was not in place, is that the question?
Yeah. Yeah. The sales target was put in place before the Thermo Fisher deal became a reality.
Well, look, I think that if you're looking at how to commercialize transplantation products, you can either do that directly or through partners. Um, and we made a strategic decision that, at the time, we believed partnering with Thermo would make the most sense and has the lowest risk to get to the targets.
Okay, well. And it seems like you're very confident that you will be able to deliver on the 30% organic growth target for 2025. Very happy with those answers.
If you wish to ask a question, please dial the pound key on your telephone keypad.
And it seems like you're very confident that you will be able to deliver on the 30% organic growth target for 2025. If there are no more questions.
Or questions at this time. So I hand the conference back to the speakers for any closing comments.
All right. And it seems like you're very confident that you will be able to deliver on the 30% organic growth target for 2025. No more questions. So, um, again, thank you everyone for joining our call today. We certainly feel a very good momentum and energy in the company today, and look forward to continuing to deliver on all our initiatives that we recently initiated. So thank you, everyone.



















